# Day Regimes of CONbercept on CytokinEs of PDR Patients Undergoing Vitrectomy - Trial (CONCEPT)

> **NCT03506750** · PHASE4 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 200 (estimated)

## Conditions studied

- Proliferative Diabetic Retinopathy
- VEGF Overexpression

## Interventions

- **DRUG:** IVC
- **PROCEDURE:** Blood and aqueous humor at the time of IVC
- **PROCEDURE:** Collect blood, aqueous humor, and initial vitreous at the time of surgery.
- **PROCEDURE:** IVC-sham

## Key facts

- **NCT ID:** NCT03506750
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-03
- **Primary completion:** 2018-09-01
- **Final completion:** 2018-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2018-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03506750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03506750, "Day Regimes of CONbercept on CytokinEs of PDR Patients Undergoing Vitrectomy - Trial (CONCEPT)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03506750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*